

# HPC simulations for in-silico trials in humans: therapeutic strategies in acute myocardial ischemia

**Hector Martinez-Navarro**


Xin Zhou

Ana Mincholé

Alfonso Bueno-Orovio

Blanca Rodriguez

Computational Cardiovascular Science group  
Department of Computer Science,  
University of Oxford, UK




# Acute myocardial ischemia

Coronary artery disease (CAD) is the most common cause of death globally [1]. There are 2.6 million people living in UK with CAD. About 73,000 die yearly [2].


[1] GBD 2015 Mortality and Causes of Death Collaborators (2016)

[2] <https://heartuk.org.uk>

## Coronary occlusion causes myocardial ischemia




## Electrophysiological heterogeneities



## Formation of reentrant patterns

Most pro-arrhythmic stage:  
10-15 min post occlusion



Janse et al., 1980

# Aims

How does variability of the ischemic region affect arrhythmogenesis?

Can we use in-silico trials to explain the cardiotoxic effects of certain drugs?


Can we use the results to suggest new effective anti-arrhythmic strategies?

# Computational models of cardiac electrophysiology

## In-silico trials

- Based on human data: results translatable to human
- Suitable alternative when ethics or technical limitations

**in-vitro testing**



**animal testing**



**clinical trials**



## Drug development

- Early prediction of drug cardiotoxicity
- Reduction, refinement and replacement of animal experimenting


## Major challenges to tackle

- High variability in drug response
- Variable diseased conditions
- Concomitant medications

**in-silico trials**






# Computational models of cardiac electrophysiology



# How is the whole organ model built?


- Ventricular/torso mesh based on more than **3.2 million nodes** from CT scans.
- Each node in the ventricles' domain is an **instance of the ORd** cardiac cell model.  
2.5 million ORd instances coupled to each other.
- Electrical propagation equations solved with **FEM** using a **adaptative integration** method.






# Methods

## Human biventricular model of acute ischemia



- Fibre orientation.
- Transmural and apicobasal heterogeneities.
- Realistic activation sequence.
- Realistic conduction velocities.




Design of **multiple scenarios** simulating variability in the ischemic region.

# Validation

## Cell/tissue level [Dutta 2017]

- Action potential shortening
- Refractoriness prolongation
- Conduction velocity reduction

in agreement with human measurements [Taggart 2000]



## Whole organ level [Martinez-Navarro 2019]


Comparison of the simulated ECG obtained from the model under transmural ischemia conditions and records from a patient in the STAFF III database.




# Validation

## ECG signature of SCN5A mutations leading to Na<sup>+</sup> channel block

Type I II III Brugada syndrome, Sethi et al. (2014)




Computer simulations of ischemia co-existing with varying Na<sup>+</sup> channel alterations



## The model reproduces

- Realistic ECG morphology
- Ischemia induced ST elevation
- J waves under Na<sup>+</sup> block conditions


# Stimulation protocol to assess reentry vulnerability




NO REENTRY



Vulnerability window




REENTRY



Approx. 500 simulations, each of them using 720 cores, 3-12h  
Results: ~80 GB each simulation

# Results



Na<sup>+</sup> current availability is shown to have a crucial role in ischemia-induced arrhythmogenesis.

## 25% Na<sup>+</sup> increase

Gene therapy, such as SkM1 overexpression

## BASELINE

Normal ionic conditions

## 25% Na<sup>+</sup> block

Na<sup>+</sup> channel blockers, such as flecanide or encanide

## 50% Na<sup>+</sup> block

SCN5A mutations, such as BrS or Lenègre's disease

# Conclusions

## ♥ **Computer models of cardiac electrophysiology**

- ✓ **Human-based and multiscale**
- ✓ **Population of models** take into account inter-subject variability

## ♥ **Human in-silico drug trials**

- ✓ Early prediction of **clinical risk of drug-induced arrhythmias**
- ✓ Potential to replace pre-clinical animal experiments

## ♥ **3D whole-heart simulations**

- ✓ Suitable for understanding arrhythmogenic mechanisms
- ✓ Identification of therapy targets oriented to specific pathologies